Mga Batayang Estadistika
| CIK | 1068796 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Maxygen Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 5, 2015 |
MAXY / Maxygen Inc / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MAXYGEN INC (Name of Issuer) Common Stock (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2014 |
MAXY / Maxygen Inc / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MAXYGEN INC (Name of Issuer) Common Stock (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-28401 Maxygen, Inc. (Exact name of registrant as specified in its charte |
|
| September 23, 2013 |
POS AM As filed with the Securities and Exchange Commission on September 23, 2013 Registration No. |
|
| September 23, 2013 |
POS AM As filed with the Securities and Exchange Commission on September 23, 2013 Registration No. |
|
| September 23, 2013 |
POS AM As filed with the Securities and Exchange Commission on September 23, 2013 Registration No. |
|
| September 23, 2013 |
POS AM As filed with the Securities and Exchange Commission on September 23, 2013 Registration No. |
|
| September 23, 2013 |
MAXY / Maxygen Inc / Yakira Capital Management, Inc. - SC 13G Passive Investment SC 13G 1 v355637sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Maxygen, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 577776107 (CUSIP Number) July 29, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| September 17, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on September 17, 2013 Registration No. |
|
| August 30, 2013 |
Maxygen Announces Filing of Certificate of Dissolution; Delisting from NASDAQ EX-99.1 3 d591659dex991.htm EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Filing of Certificate of Dissolution; Delisting from NASDAQ SAN MATEO, Calif., August 29, 2013 - Maxygen, Inc. (Nasdaq: MAXY), announced today that it has filed a certificate of dissolution with the Secretary of State of |
|
| August 30, 2013 |
EX-4.1 2 d591659dex41.htm EX-4.1 Exhibit 4.1 CERTIFICATE OF DISSOLUTION OF MAXYGEN, INC. Pursuant to Section 275 of the General Corporation Law of the State of Delaware Maxygen, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The dissolution of the Corporation has been duly authorized by the |
|
| August 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 13, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 13, 2013 |
EX-99.1 2 d581604dex991.htm EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Approval of Dissolution by Shareholders —Initial liquidating distribution of $2.50 per share to be paid on or about August 29, 2013— SAN MATEO, Calif., August 12, 2013 — Maxygen, Inc. (Nasdaq: MAXY), today announced that |
|
| August 7, 2013 |
Maxygen Reports Second Quarter 2013 Financial Results EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Reports Second Quarter 2013 Financial Results SAN MATEO, Calif., August 7, 2013 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial results for the quarter ended June 30, 2013. Second Quarter 2013 Financial Results Maxygen r |
|
| August 7, 2013 |
Form 10-Q Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| June 28, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| June 28, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 3, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 3, 2013 |
EX-99.1 3 d547321dex991.htm EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Board Decision to Dissolve the Company —Company expects to make initial liquidating distribution of between $2.45 and $2.50 per share— SAN MATEO, Calif., June 3, 2013 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical co |
|
| June 3, 2013 |
PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF MAXYGEN, INC. Exhibit 2.1 PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF MAXYGEN, INC. The following Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”), dated as of May 30, 2013, shall effect the dissolution and complete liquidation of Maxygen, Inc., a Delaware corporation (the “Company”), in accordance with Sections 275, 278, 280, 281 and other applicable provisions of the Delaware Gener |
|
| June 3, 2013 |
Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 3, 2013 |
EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Board Decision to Dissolve the Company —Company expects to make initial liquidating distribution of between $2.45 and $2.50 per share— SAN MATEO, Calif., June 3, 2013 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced that |
|
| June 3, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 3, 2013 |
PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF MAXYGEN, INC. EX-2.1 Exhibit 2.1 PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF MAXYGEN, INC. The following Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”), dated as of May 30, 2013, shall effect the dissolution and complete liquidation of Maxygen, Inc., a Delaware corporation (the “Company”), in accordance with Sections 275, 278, 280, 281 and other applicable provisions of the Delawar |
|
| May 3, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 3, 2013 |
Maxygen Reports First Quarter 2013 Financial Results Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Reports First Quarter 2013 Financial Results SAN MATEO, Calif., May 3, 2013 – Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2013. First Quarter 2013 Financial Results Maxygen |
|
| March 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2013 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 12, 2013 |
Maxygen Reports Fourth Quarter and Year End 2012 Financial Results EX-99.1 Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Reports Fourth Quarter and Year End 2012 Financial Results SAN MATEO, Calif., March 12, 2013 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2012. Fourth Q |
|
| February 13, 2013 |
MAXY / Maxygen Inc / Alistair Capital Management, L.L.C. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. |
|
| February 11, 2013 |
MAXY / Maxygen Inc / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MAXYGEN INC (Name of Issuer) Common Stock (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 17, 2013 |
MAXY / Maxygen Inc / HOWARD RUSSELL J - AMENDMENT NO. 8 TO SCHEDULE 13G Passive Investment SC 13G/A 1 d469109dsc13ga.htm AMENDMENT NO. 8 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Maxygen, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this St |
|
| November 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 6, 2012 |
Maxygen Announces Third Quarter 2012 Financial Results Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Third Quarter 2012 Financial Results SAN MATEO, Calif., November 6, 2012 – Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced financial and business results for the quarter ended September 30, 2012. Third Quarter 2012 Financial Results M |
|
| November 6, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2012 |
Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Announces Second Quarter 2012 Financial Results and Business Update —Board of Directors authorizes cash distribution of approximately $100.0 million to stockholders— SAN MATEO, Calif., August 7, 2012 — Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today anno |
|
| August 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) |
|
| June 7, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| May 14, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| May 14, 2012 |
Maxygen to Receive $30 Million Payment from Bayer Press Release Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen to Receive $30 Million Payment from Bayer SAN MATEO, Calif., May 14, 2012—Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced that it will receive a $30.0 million payment from Bayer HealthCare LLC in connection with Bayer’s contin |
|
| May 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 7, 2012 |
Maxygen Reports First Quarter 2012 Financial Results Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Reports First Quarter 2012 Financial Results SAN MATEO, Calif., May 7, 2012 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012. First Quarter 2012 Financial Results Maxygen |
|
| April 26, 2012 |
DEF 14A 1 d337481ddef14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the C |
|
| April 26, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d337834ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission on |
|
| March 8, 2012 |
Press Release Exhibit 99.1 Maxygen, Inc. 411 Borel Avenue Suite 616 San Mateo, CA 94402 650.241.2292 main 650.257.5892 fax www.maxygen.com Maxygen Reports Fourth Quarter and Year End 2011 Financial Results SAN MATEO, Calif., March 8, 2012 — Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter and year ended December 31, 2011. Fou |
|
| March 8, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| February 14, 2012 |
EX-99.1 2 d287556dex991.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value, of Maxygen, Inc., and further agree that this |
|
| February 14, 2012 |
MAXY / Maxygen Inc / CONUS PARTNERS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2012 |
MAXY / Maxygen Inc / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MAXYGEN INC (Name of Issuer) Common Stock (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2012 |
MAXY / Maxygen Inc / Alistair Capital Management, L.L.C. - SCHEDULE 13G Passive Investment SC 13G 1 d287556dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Maxygen, Inc. (Name of issuer) Common Stock, $0.0001 par value (Title of class of securities) 577776107 (CUSIP number) December 31, 2 |
|
| February 13, 2012 |
MAXY / Maxygen Inc / HOWARD RUSSELL J - SCHEDULE 13G AMENDMENT NO. 7 Passive Investment Schedule 13G Amendment No. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Maxygen, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 577776107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2012 Maxygen, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-28401 77-0449487 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
